HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical ...
HFK1 is the company’s groundbreaking drug encapsulated immunoliposome for solid tumors with HER2 low expression HANGZHOU, China–(BUSINESS WIRE)–HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes …